Skip to main content
Premium Trial:

Request an Annual Quote

Valentis Licenses GeneSwitch to Schering, Pockets $1.1M

NEW YORK, Dec. 20 - Schering will pay Valentis $1.1 million for the right to use its GeneSwitch gene-regulation technology for internal drug discovery.


Terms of the deal also call for Schering to get exclusive, worldwide rights to Valentis' PINC polymer-based synthetic gene-delivery technology. The German pharma firm said it will use GeneSwitch in up to two of its genes and consider an option for non-exclusive rights to the PINC technology for a third gene.


Click here for more information.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.